Document is current
Any future updates will be listed below
-
Authors
Pollyea, Daniel
Kerre, Tessa
Deeren, Dries https://orcid.org/0000-0001-9599-2142
Beguin, Yves
Lin, Tara L. https://orcid.org/0000-0002-0242-6449
Sallman, David A. https://orcid.org/0000-0003-0504-8233
Anguille, Sebastien https://orcid.org/0000-0002-1951-6715
Blum, William G.
Flament, Anne
Breman, Eytan
Lonez, Caroline https://orcid.org/0000-0002-9230-3855
-
Funding
Funding for this research was provided by:
Service Public de Wallonie (8087 and 8088)
- License Information
-
More Information
Article History
Received: 23 June 2025
Revised: 16 August 2025
Accepted: 8 September 2025
First Online: 15 September 2025
Competing interests
: DP, TK, DD, YB, TLL, DAS, SA, and WGB were Investigators of the DEPLETHINK or CYCLE-1 clinical trials, sponsored by Celyad Oncology SA. DD: Consultancy for Novartis, BMS, Incyte, Alexion, Sobi, Takeda, Roche, Servier, CSL Behring; research funding by Alexion, Sobi, Roche, Novartis, Amgen. TLL: Consulting or advisory role: Servier, Jazz Pharmaceuticals, Syndax, Daiichi Sankyo; research funding to the institution: Bio-Path Holdings, Inc, Astellas Pharma, Celyad Oncology, Aptevo Therapeutics, Cleave Biosciences, CicloMed, Jazz Pharmaceuticals, Cardiff Oncology, Kura Oncology. DAS: Research funding from Aprea; advisory board member at AbbVie, Agios, Aprea, Bristol Myers Squibb, Intellia, Kite, Novartis, Shattuck Labs, and Syndax; consultant to Magenta, Novartis, and Takeda; speakers’ bureau at Bristol Myers Squibb and Incyte. AF, EB, and CL were employees of Celyad Oncology SA during the realization of this work. The research conducted within the manuscript may lead to the development of products which may be licensed by Celyad Oncology SA. The other authors declare no conflicts of interest.
